文献速递肝病

糖皮质激素治疗药物性肝损伤的潜在获益及无严重风险:一项国际多中心倾向性评分匹配分析

Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis.
PubMed 文献 · Aliment Pharmacol Ther · 2022-12-22

该研究基于西班牙DILI登记处和印第安纳大学医学院的724例特质性药物性肝损伤患者,其中106例接受糖皮质激素治疗,618例未接受治疗。倾向性评分匹配分析显示,糖皮质激素未增加急性肝衰竭风险(OR=0.65,95%CI 0.18-2.40,p=0.518),且与肝酶正常化率显著更高相关(HR=1.84,95%CI 1.02-3.32,p=0.043),尤其在30天内未缓解的严重损伤患者中(HR=2.79,95%CI 1.20-6.50,p=0.018)。结论认为糖皮质激素治疗未恶化DILI患者结局,并与严重DILI患者肝酶正常化率更高相关。

要点

  • 糖皮质激素未增加DILI患者急性肝衰竭风险(OR=0.65,95%CI 0.18-2.40,p=0.518)。
  • 糖皮质激素组肝酶正常化率显著高于未治疗组(HR=1.84,95%CI 1.02-3.32,p=0.043)。
  • 严重损伤且30天内未缓解者中,糖皮质激素与更高正常化率相关(HR=2.79,95%CI 1.20-6.50,p=0.018)。

核心结论

  • 糖皮质激素治疗未恶化DILI患者结局,且与严重DILI患者肝酶正常化率更高相关。

研究设计与样本

  • 研究分析了西班牙DILI登记处和印第安纳大学医学院的特质性DILI病例,共纳入724例患者,其中106例接受糖皮质激素治疗,618例未接受任何治疗,并采用最近邻倾向性评分匹配分析。

主要发现

  • 在80对倾向性评分匹配患者中,糖皮质激素使用与急性肝衰竭风险增加无关(OR=0.65,95%CI 0.18-2.40,p=0.518)。
  • 在41对倾向性评分匹配患者的Cox回归模型中,糖皮质激素组肝酶正常化率显著高于未治疗组(HR=1.84,95%CI 1.02-3.32,p=0.043)。
  • 在30天内未缓解的严重损伤患者中,糖皮质激素组肝酶正常化率显著更高(HR=2.79,95%CI 1.20-6.50,p=0.018)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of corticosteroids to treat patients with idiosyncratic drug-induced liver injury (DILI) relies on empirical clinical decisions. AIM: To investigate the relationship between corticosteroids and risk of acute liver failure (ALF) in patients with DILI and to assess if corticosteroid therapy was associated with improved outcomes in DILI patients. METHODS: We analysed bona fide idiosyncratic DILI cases from the Spanish DILI Registry and Indiana University School of Medicine. Patients treated with corticosteroids were compared to those who did not receive any treatment. Nearest neighbour propensity score matching analyses were conducted. RESULTS: We enrolled 724 patients, 106 under corticosteroid therapy, in whom there was over-representation of more severe injury and autoimmune features, and 618 who did not receive any treatment. In an analysis of 80 pairs of propensity score-matched patients, corticosteroid administration was not associated with an increased risk of developing ALF (odds ratio = 0.65; 95% confidence interval [CI]: 0.18-2.40; p = 0.518). Furthermore, in an additional analysis, a Cox regression model that included 41 propensity score-matched pairs showed that patients receiving corticosteroids had a significantly higher normalisation rate of liver enzymes than untreated patients (hazard ratio [HR] = 1.84; 95% CI: 1.02-3.32; p = 0.043), particularly in patients with serious injury who did not resolve within 30 days (HR = 2.79; 95% CI: 1.20-6.50; p = 0.018). CONCLUSION: Corticosteroid therapy did not worsen outcome in DILI patients. Indeed, corticosteroid administration was associated with a greater rate of normalisation of liver enzymes in patients with serious DILI.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Niu H, Ma J, Medina-Caliz I, et al. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis. Aliment Pharmacol Ther. 2022. PMID: 36547393. doi:10.1111/apt.17373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。